公开(公告)号：EP4294455A1

公开(公告)日：2023-12-27

申请号：EP22755548.9

申请日：2022-02-17

申请人： RemeGen Co., Ltd.

发明人： FANG, Jianmin ,  SU, Xiaohong ,  GUO, Xuguang ,  HE, Ruyi

IPC分类号： A61K47/68 ,  A61K39/395 ,  C07K16/28 ,  A61P35/00 ,  A61P35/04

公开(公告)号：EP4074337A1

公开(公告)日：2022-10-19

申请号：EP20899392.3

申请日：2020-12-09

申请人： RemeGen Co., Ltd.

发明人： XU, Qiaoyu ,  LI, Zhuanglin ,  YAO, Xuejing ,  FANG, Jianmin

IPC分类号： A61K39/395 ,  C07K19/00 ,  A61K38/17 ,  A61K38/16 ,  A61P25/00 ,  A61P35/00 ,  A61P37/02

摘要： Disclosed is a pharmaceutical formulation containing a mixture of a non-reducing sugar, a TACI-Fc fusion protein and at least one amino acid. The pharmaceutical formulation has the characteristics of reducing particulate matter, reducing aggregate formation, improving the stability, improving the appearance of a freeze-dried powder, etc.

公开(公告)号：EP4442702A1

公开(公告)日：2024-10-09

申请号：EP23819132.4

申请日：2023-06-07

申请人： RemeGen Co., Ltd.

发明人： FANG, Jianmin ,  WANG, Wenxiang

IPC分类号： C07K14/705 ,  A61P37/00

CPC分类号： C07K14/705 ,  A61P37/00

摘要： Provided are a drug, a dosage regimen, an administration interval and an administration mode for treating myasthenia gravis by means of using TACI-Fc fusion protein. Results show that the provided TACI-Fc fusion protein exhibits a good clinical efficacy and safety in the treatment of patients with myasthenia gravis.

公开(公告)号：EP3811979A1

公开(公告)日：2021-04-28

申请号：EP20776430.9

申请日：2020-03-25

申请人： RemeGen Co., Ltd.

发明人： LI, Zhuanglin ,  XU, Qiaoyu ,  YAO, Xuejing ,  BAO, Qianjing ,  FANG, Jianmin

IPC分类号： A61K47/68 ,  A61K47/65 ,  A61K9/19 ,  A61P35/00

摘要： A pharmaceutical preparation comprising a mixture of a nonreducing sugar, a recombinant humanized anti-Her2 monoclonal antibody-MMAE conjugate, and a surfactant. The pharmaceutical preparation has the characteristics of reducing particulate matters, reducing aggregate formation, improving the stability of a conjugate, improving the appearance of freeze-dried powder, etc.

公开(公告)号：EP4316521A2

公开(公告)日：2024-02-07

申请号：EP23202349.9

申请日：2020-03-25

申请人： RemeGen Co., Ltd.

发明人： LI, Zhuanglin ,  XU, Qiaoyu ,  YAO, Xuejing ,  BAO, Qianjing ,  FANG, Jianmin

IPC分类号： A61K47/20

摘要： A pharmaceutical preparation comprising a mixture of a nonreducing sugar, a recombinant humanized anti-Her2 monoclonal antibody-MMAE conjugate, and a surfactant. The pharmaceutical preparation has the characteristics of reducing particulate matters, reducing aggregate formation, improving the stability of a conjugate, improving the appearance of freeze-dried powder, etc.

公开(公告)号：EP4056596A1

公开(公告)日：2022-09-14

申请号：EP21770764.5

申请日：2021-03-19

申请人： RemeGen Co., Ltd.

发明人： FANG, Jianmin

IPC分类号： C07K19/00 ,  C12N15/62 ,  C12N15/63 ,  A61K38/17 ,  A61K39/395 ,  A61P35/00 ,  G01N33/574

摘要： Provided is a bispecific fusion protein having a novel structure. A second binding structural domain is inserted into an IgG hinged region in a full length by means of an optional peptide joint. The fusion protein has the same expression and production advantages as those of IgG, does not influence the binding activity of an Fab region of the fusion protein and further improves the stability and obtains a higher half life. In addition, the binding activity of the second binding structural domain to a target binding site is significantly improved with respect to the binding activity of a monomer corresponding to a soluble natural binding fragment to a corresponding target.

公开(公告)号：EP4316521A3

公开(公告)日：2024-04-10

申请号：EP23202349.9

申请日：2020-03-25

申请人： RemeGen Co., Ltd.

发明人： LI, Zhuanglin ,  XU, Qiaoyu ,  YAO, Xuejing ,  BAO, Qianjing ,  FANG, Jianmin

IPC分类号： A61K47/68 ,  A61K47/65 ,  A61K9/19 ,  A61P35/00 ,  A61K9/08 ,  A61K38/00 ,  A61K39/395 ,  A61K47/20

摘要： A pharmaceutical preparation comprising a mixture of a nonreducing sugar, a recombinant humanized anti-Her2 monoclonal antibody-MMAE conjugate, and a surfactant. The pharmaceutical preparation has the characteristics of reducing particulate matters, reducing aggregate formation, improving the stability of a conjugate, improving the appearance of freeze-dried powder, etc.

公开(公告)号：EP4335873A1

公开(公告)日：2024-03-13

申请号：EP22806632.0

申请日：2022-05-07

申请人： RemeGen Co., Ltd.

发明人： FANG, Jianmin ,  LI, Yuanhao ,  ZHU, Marie M. ,  JIANG, Jing ,  SHEN, Yuelei ,  LI, Shenjun ,  LUO, Wenting ,  ZHANG, Xiaoping ,  WANG, Lili ,  WANG, Ling ,  ZHANG, Qinbin ,  YANG, Fang

IPC分类号： C07K16/28 ,  A61K47/68 ,  A61K39/395 ,  A61P35/00

摘要： Provided are an antibody targeting Claudin 18.2, an antibody-drug conjugate, and use thereof in treatment of cancer. Also provided are a nucleotide encoding the Claudin 18.2 antibody, a polynucleotide combination, an expression vector, an expression vector combination, a pharmaceutical composition comprising the Claudin 18.2 antibody and the antibody-drug conjugate, and an application thereof in preparation of a medication for treatment or prevention of cancer.

公开(公告)号：EP4292603A1

公开(公告)日：2023-12-20

申请号：EP22855425.9

申请日：2022-08-09

申请人： RemeGen Co., Ltd.

发明人： FANG, Jianmin ,  WANG, Wenxiang

IPC分类号： A61K38/17 ,  A61K39/395 ,  C07K19/00 ,  A61P37/02

摘要： The present invention relates to a drug for treating IgA nephropathy with a TACI-Fc fusion protein, a dose regimen, an administration interval and an application method. Results show that the urine protein levels of patients in a treatment group are significantly reduced compared with a baseline, and are statistically significant compared with a placebo group. In addition, a significant difference between the treatment group and the placebo control group in multiple secondary endpoints of clinical trials also exists.

公开(公告)号：EP3858862A9

公开(公告)日：2021-10-06

申请号：EP20859087.7

申请日：2020-08-25

申请人： RemeGen Co., Ltd.

发明人： FANG, Jianmin ,  JIANG, Jing ,  LI, Shenjun ,  ZHAO, Guorui

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61P27/00

摘要： Provided in the present invention is a PD-L1 immunosuppressant, and specifically provided are a monoclonal antibody capable of targeting PD-L1, and nucleotides, combinations of polynucleotides, expression vectors and combinations of expression vectors encoding the antibody. Also provided in the present invention is a conjugate or pharmaceutical composition containing the above-mentioned anti PD-L1 antibody. Further provided in the present invention is the use of the above-mentioned anti PD-L1 antibody, nucleotides, combinations of polynucleotides, expression vectors, combinations of expression vectors, conjugate or pharmaceutical composition in the preparation of a medicament for treating or preventing cancers.